Caplin Point Laboratories Ltd. benchmarking: Perfomance to industry peers

Financial

	Caplin Point Lab	Gufic Biosciences	Gland Pharma
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	52.0 .	n/a	378.0 .
Number of ANDA's Approved By USFDA	42.0 .	n/a	329.0 .
R&D as a % of Total Sales	4.02 %	1.28 %	5.8 %
Financials
5 yr Average ROE	19.84 %	16.89 %	12.02 %
5yr average Equity Multiplier	1.15	2.16	1.15
5yr Average Asset Turnover Ratio	0.68	0.75	0.51
5yr Avg Net Profit Margin	25.35 %	10.24 %	20.79 %
Price to Book	4.58	5.49	2.95
P/E	24.59	60.82	35.69
5yr Avg Cash Conversion Cycle	70.68 Days	-15.25 Days	69.81 Days
Inventory Days	66.07 Days	71.73 Days	118.26 Days
Days Receivable	110.7 Days	106.89 Days	99.92 Days
Days Payable	85.23 Days	179.29 Days	107.43 Days
5yr Average Interest Coverage Ratio	633.04	8.9	183.05
5yr Avg ROCE	24.45 %	17.89 %	16.55 %
5yr Avg Operating Profit Margin	31.52 %	18.12 %	29.26 %
5 yr average Debt to Equity	0.0	0.67	0.01
5yr CAGR Net Profit	17.23 %	-2.66 %	-6.87 %
5yr Average Return on Assets	17.23 %	7.7 %	10.65 %
Shareholdings
Promoter Holding	70.57 %	72.5 %	51.83 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	1.69 %	-2.5 %	-6.03 %
Change in Mutual Fund Holding (3 Yrs)	0.74 %	2.45 %	11.71 %

Business

	Caplin Point Lab	Gufic Biosciences	Gland Pharma
Product Wise Break-Up	Product Wise Break-Up Formulations 75.0 Branded Generics 25.0 API 0 Muscle Relaxants 0 Cardiovascular 0 Proton pump inhibitors 0 Anti-fungals 0 Anti-bacterials 0 International 0 CMO 0 Domestic 0 Injectables 0 Pharmaceuticals 0	Product Wise Break-Up Formulations 0 Muscle Relaxants 0 Cardiovascular 0 CMO 30.0 Active Pharmaceutical Ingredient (API) 5.0 Proton pump inhibitors 0 Domestic Pharmaceuticals 50.0 Pharmaceuticals 0 Anti-fungals 0 Anti-bacterials 0 International 15.0 Branded Generics 0 Injectables 0	Product Wise Break-Up Formulations 0 Muscle Relaxants 0 Cardiovascular 0 CMO 0 API 0 Proton pump inhibitors 0 Domestic 0 Pharmaceutical 100.0 Anti-fungals 0 Anti-bacterials 0 International 0 Branded Generics 0 Injectables 0
Location Wise Break-Up	Location Wise Break-Up Latin America 76.0 USA 18.0 Africa 6.0 India 0 South America 0 Australia 0 North America 0 Europe 0 Asia 0 Rest of the World 0 Canada, Australia & New Zealand 0 Canada 0	Location Wise Break-Up North America 1.19 Africa 2.95 Rest of the World 0 Canada, Australia & New Zealand 0 Asia Pacific 6.04 Canada 0 Latin America 0 Europe 7.54 South America 2.37 USA 0 India 79.83 Australia 0.08	Location Wise Break-Up North America 0 Africa 0 Rest of the World 0 Canada, Australia & New Zealand 3.28 Asia 0 Canada 0 Latin America 0 Europe 19.15 South America 0 USA 55.68 India 4.47 Australia 0 Others 17.42
Distribution Channel	Distribution Channel Distribution 45.0 Pharmacy and Dietary 35.0 Tender Business 20.0 B2C 0 B2B 0	-	Distribution Channel Distribution 0 Tender Business 0 B2B 99.0 Pharmacy and Dietary 0 B2C 1.0
Manufacturing Break-Up	Manufacturing Break-Up India 73.0 China 27.0	-	-

Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd.

Financial

Business

SIGN UP FOR FREE